Table 2.
KEYNOTE-052 [29], Abstract #4524 |
IMvigor210 (Cohort 1) [28], Abstract #4523 |
EORTC 30986 [25], Gemcitabine/carboplatin |
|
---|---|---|---|
Study population (n) | 370 | 119 | 238 |
ORR (%) | 28.9 | 24 | 36 |
CR Rate (%) | 8.1 | 8 | 6.1 |
Median OS (months) | 11.5 | 16.3 | 9.3 |
1-Year OS rate (%) | 47.5 | 58 | 37 |
2-Year OS rate (%) | – | 41 | 18 |
ORR objective response rate, OS overall survival, CR complete response